Questions? Call us at 800-810-7790

Not meeting your cholesterol goals with pravastatin?

Switch to ZYPITAMAG (pitavastatin)

Statin Metabolism Pitavastatin Simvastatin Pravastatin Rosuvastatin Atorvastatin Comparison

Key Features of ZYPITAMAG (pitavastatin)


ZYPITAMAG is a third-generation statin that is used alongside changes to diet and exercise to help lower cholesterol in adults.

  • Similar metabolism to pravastatin
  • Superior in LDL-C reduction compared to pravastatin
  • Reduces LDL-C up to 45% and increases HDL-C up to 7%
  • Compatible with grapefruit juice
  • Taken once daily, with or without food

Not at your cholesterol goal with Pravastatin?

Pravastatin is a great option for individuals on multiple medications due to its unique metabolism pathway. It may be why your healthcare provider prescribed it.

However, pravastatin’s safety profile comes with a trade-off in terms of potency. Pravastatin is a low- to moderate-intensity statin, and many people may not reach their cholesterol targets with it.


ZYPITAMAG (pitavastatin) is a Stronger Statin with a Similar Metabolism


  • Similar Metabolism: Both pitavastatin and pravastatin are metabolized differently than most other statins which reduces the risk of drug interactions compared to other statins.

  • Better Cholesterol Lowering Ability: ZYPITAMAG (pitavastatin) more effective at lowering LDL cholesterol (the “bad” cholesterol) and other lipid parameters than pravastatin.

We Make Accessing ZYPITAMAG Easy

We will determine the most cost-effective option for you to access ZYPITAMAG (pitavastatin) - whether its through insurance or by cash. No matter what, the most you will ever pay for ZYPITAMAG is $1.15/day - or $34.50/month.

Plus enjoy free home delivery on all orders.


Don't have a prescription? If you don't have a prescription, you can request one with this form and we'll contact your doctor for you.

Have medication questions on ZYPITAMAG?
Talk with a pharmacist today.

Call us for a free pharmacy consult.

800-810-7790

Statin Metabolism

Comparing ZYPITAMAG and Pravastatin's Metabolism


Drug interactions have a lot to do with how our body metabolizes them.

Most statins are processed by our body through an enzyme family called cytochrome 450, or CYP450 for short. 70-80% of drugs are also metabolized by this pathway.

Both ZYPITAMAG and pravastatin bypass this pathway. As a result, both ZYPITAMAG and pravastatin have reduced potential to interact with other medications compared to the other statins.

Dive Into the Data Comparing ZYPITAMAG and Pravastatin


Several studies have compared Pitavastatin and Pravastatin's ability to lower cholesterol.


Before delving into the data yourself, here's a simple guide to help you understand this information:

  • LDL-C (Low-Density Lipoprotein Cholesterol): Often known as 'bad cholesterol'. It's a type of cholesterol that can contribute to artery blockages and heart issues.
  • HDL-C (High-Density Lipoprotein Cholesterol): Often called 'good cholesterol'. Having higher levels of HDL-C is generally beneficial for heart health, as it helps remove excess cholesterol from the blood vessels.
  • Triglycerides: These are a kind of fat found in your bloodstream. High triglyceride levels are linked to a greater risk of heart disease.
  • ApoB (Apolipoprotein B): This serves as a marker for cholesterol that can lead to artery clogging, forming plaques on the artery walls. Higher ApoB values indicate an increased risk of developing heart-related problems like atherosclerosis (narrowing of arteries) and potentially heart attacks.
  • hsCRP (High-Sensitivity C-Reactive Protein): This acts as a sign of inflammation in the body. Elevated hsCRP levels are associated with an increased likelihood of heart disease.

STUDY 1

Lowering Cholesterol In Adults

Pitavastatin has shown a superior ability to lower LDL-cholesterol compared to pravastatin in adults with high cholesterol1-2.


Mean percent changes at week 12
Pitavastatin
4 mg
Pravastatin
40 mg
ApoB -27% -18%
Triglycerides -16% -13%
HDL-C +5% +6%
Pitavastatin vs Pravastatin

STUDY 2

Lowering Cholesterol In Adults 65 years and older

Pitavastatin has shown a superior ability to lower LDL-cholesterol compared to pravastatin in those with high cholesterol who were older than 65 years of age 3.


Mean percent changes at week 12
Pitavastatin
4 mg
Pravastatin
40 mg
ApoB -37% -28%
Triglycerides -22% -15%
HDL-C +4% +1%
hsCRP -0.9% +0.6%
Pitavastatin vs Pravastatin

STUDY 3

Lowering Cholesterol In Those Living With HIV

Managing HIV is now possible with new drug developments. Unfortunately, it means patients are taking a lot of medications which can increase drug interactions. Pitavastatin and Pravastatin are both acceptable options give their unique metabolism.


Pitavastatin has shown a superior ability to lower LDL-cholesterol compared to pravastatin in those with high cholesterol who were living with HIV4.


Mean percent changes at week 12
Pitavastatin
4 mg
Pravastatin
40 mg
ApoB -26% -19%
Triglycerides -3% -4%
HDL-C +5% +6%
hsCRP -12% 0%
Pitavastatin vs Pravastatin in People Living with HIV

References

1 Sponseller CA et al. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial. Clinical Therapeutics. 2014;36(8):1211-1222.
2 Miller PE et al. Pitavastatin 4 mg Provides Significantly Greater Reduction in Remnant Lipoprotein Cholesterol Compared With Pravastatin 40 mg: Results from the Short-term Phase IV PREVAIL US Trial in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia. Clinical Therapeutics. 2016;38(3):603-609.
3 Stender S et al. Pitavastatin shows greater lipid-lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia. European Journal of Preventative Cardiology. 2013;20(1):40-53.
4 Aberg JA et a. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial. Lancet HIV. 2017;4:e284-94.